(lp0
S"Why Nektar Therapeutics Inc. Is Rising Today Motley Fool - 14 hours ago Nektar announced the results of its phase 3 SUMMIT-07 trial. This study was testing its compound NKTR-181 as a hopeful treatment for patients with moderate to severe chronic lower back pain.Nektar Therapeutics' stock jumps after positive results of its pain treatment drug - MarketWatchNektar Therapeutics Posting Substantial Gain In Afternoon Trading - Nasdaq"
p1
aS"BRIEF-Nektar Therapeutics says NKTR-181 meets primary, secondary endpoints in ... Reuters - 18 hours ago March 20 Stock futures pointed to a lower opening for Canada's main stock index on Monday after financial leaders of the world's biggest economies dropped a pledge to keep global trade free and open."
p2
aS"Can this company's pain-fighting drug smash America's opioid crisis? San Francisco Business Times - 16 hours ago Facing skepticism, the company says its drug enters the brain slowly, so pain-drug addicts don't get the euphoric rush they seek, but patients get effective pain relief."
p3
aS"Nektar Therapeutics: Touches near 11-year high Times of India - 14 hours ago ... ** Drugmaker's shares up as much as 35 pct at near 11-year high of $20.91. ** Stock second-top percentage gainer on Nasdaq."
p4
aS'Nektar Therapeutics  Breaks into New 52-Week High on March 20 Session Equities.com - 8 hours ago Shares of Nektar Therapeutics  broke into a new 52-week high yesterday, hitting a peak of $22.32. Shares closed at $22.11 after opening at $18.78 for a move of 42.65%.'
p5
aS"Here's What's Behind Nektar Therapeutics' 20% Move Higher Motley Fool - Mar 2, 2017 Shares of Nektar Therapeutics , a biopharmaceutical company that utilizes its proprietary intellectual property via licensing deals and through collaborations in the clinical development process to help fight cancer, autoimmune diseases ...Nektar Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results - PR Newswire Nektar Therapeutics  Loss Wider than Expected in Q4 - Yahoo Finance"
p6
aS'US STOCKS ON THE MOVE-Nektar Therapeutics, Aevi Genomics, Esperion, CytomX ... Times of India - 17 hours ago ... at $22.30 The top three Nasdaq percentage gainers premarket: ** CytomX Therapeutics, up 35.7 pct at $20.60 ** Esperion Therapeutics, up 27.4 pct at $30.15 ** Nektar Therapeutics, up 19.3 pct at $18.49 The top three Nasdaq percentage losers ...BUZZ-US STOCKS ON THE MOVE-Esperion, CytomX, Apple, Aevi Genomic - NasdaqBiotech Premarket Movers: CytomX, Aevi, Esperion - TheStreet.com'
p7
aS"Technical Reports on Biotech Stocks -- Nektar Therapeutics, Seattle Genetics ... PR Newswire  - Mar 13, 2017 Pre-market, Stock-Callers.com navigates the Biotechnology space with focus on Nektar Therapeutics , Seattle Genetics Inc. , Dynavax Technologies Corp.What are Analyst's Indicators for Nektar Therapeutics , PDC Energy, Inc ... - The USA CommerceNektar Therapeutics  Shares Bought by Comerica Bank - BNB Daily "
p8
aS'Nektar Therapeutics  Moves Lower on Volume Spike for March 17 Equities.com - Mar 17, 2017 Nektar Therapeutics  traded on unusually high volume on Mar. 17, as the stock lost 1.34% to close at $15.50. On the day, Nektar Therapeutics saw 2.38 million shares trade hands on 8,672 trades. Considering that the stock averages only a daily&nbsp;...Nektar Therapeutics  Position Boosted by State Street Corp - The Cerbat GemStock Returns: Nektar Therapeutics  is Beating Horizon Pharma plc ... - CML News'
p9
aS"Nektar Therapeutics' stock surges 16% premarket on positive pain treatment trial ForexTV.com - 18 hours ago Risk Disclaimer - By using this web site you agree to its terms and conditions. Before deciding to invest in foreign exchange you should carefully consider your investment objectives, level of experience, and risk appetite."
p10
a.